Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: An update

Alberto Spalice, Pasquale Parisi, Laura Papetti, Francesco Nicita, Fabiana Ursitti, Francesca Del Balzo, Enrico Properzi, Alberto Verrotti, Martino Ruggieri, Paola Iannetti

Research output: Contribution to journalArticlepeer-review


Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.

Original languageEnglish
Pages (from-to)135-148
Number of pages14
JournalCurrent Neuropharmacology
Issue number2
Publication statusPublished - 2010


  • Adem
  • Demyelinating disease
  • Disease-modifying therapies
  • Immune-mediate polyradiculoneuropathies
  • Immunomodulatory therapy
  • Pediatric multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Pharmacology
  • Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: An update'. Together they form a unique fingerprint.

Cite this